Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Testosterone + estradiol (oestrogenes) is a combination hormonal therapy regimen used for gender-affirming care in adolescents with gender dysphoria. In the context of the TRANSADO trial (NCT06351501) sponsored by Assistance Publique - Hôpitaux de Paris, this treatment involves the administration of testosterone (typically as a transdermal gel) to transmasculine individuals and estradiol (typically topical) to transfeminine individuals. The therapy aims to induce physical changes consistent with the individual's gender identity by activating androgen receptors or estrogen receptors, respectively. The Phase 3 study evaluates the impact of early initiation (age 14) versus standard initiation (age 16) on global functioning and quality of life.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on testosterone + estradiol (Assistance publique - Hôpitaux de Paris).